Glenmark Launches TEVIMBRA in India for Lung & Esophageal Cancers

  Published 11 months ago

Glenmark launches TEVIMBRA in India for NSCLC and ESCC, approved by CDSCO, offering an immune-oncology treatment.

  • TEVIMBRA, developed by BeiGene, treats NSCLC and ESCC in first-line and second-line settings.
  • Glenmark's first immune-oncology product in India, expanding its innovative oncology portfolio.
  • TEVIMBRA demonstrates strong efficacy and safety in global Phase 3 trials for solid tumors.

You might like these

Max Healthcare Surges on Growth Outlook

Emerald Finance Partners with Tech-Bulls

India's Joint Vessel Fleet

RPP Infra Jumps on BHEL Deal

Indian Markets Rise on US, EU Trade News

L&T Wins Massive High‑Speed Rail Track Contract

Rupee Flat Amid Geopolitical Tensions, Oil Prices Rise

News that matters the most ⚡